PyrAmes, Inc.
PyrAmes, Inc. is a Cupertino-based digital health company developing FDA-cleared Boppli® and pipeline Bosimi® continuous non-invasive blood pressure monitors, using proprietary capacitive sensors and machine-learning algorithms to serve NICU, adult inpatient, and home hypertension markets.
- Company typePrivate
- Founded2015
- HeadquartersCupertino, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PyrAmes, Inc. does
PyrAmes, Inc. is a Cupertino, California-based digital health and medical device company (founded 2015, 1-10 employees, private) that develops continuous non-invasive blood pressure (cNIBP) monitoring platforms using a proprietary capacitive-based wearable sensor paired with machine-learning neural network algorithms that infer systolic, diastolic, and mean arterial pressure from pulse waveform signals without external calibration. The company's portfolio comprises three product platforms built on a common technology stack: Boppli®, a single-use, battery-powered wearable band for neonatal and pediatric NICU patients (FDA Breakthrough Device Designation in May 2020, FDA 510(k) cleared September 2023); Bosimi®, an adult inpatient and emergency care wrist-worn band under development (not yet FDA cleared); and Bosimi@Home™, a consumer-grade wrist band paired with a mobile application for outpatient and home hypertension monitoring, also under development. Clinical validation includes a 81-infant study at Lucile Packard Children's Hospital Stanford (published in Sensors) and a pivotal five-hospital U.S./Canada study comparing Boppli to arterial lines (published in Neonatology, May 2025).
PyrAmes generates revenue through hardware sales of its devices and single-use sensor bands to hospitals, healthcare systems, and care providers. Boppli is the only commercially-shipped product and is distributed exclusively in the U.S. NICU market through Sentec (announced September 2022), a market leader in non-invasive NICU monitoring that leverages its existing customer relationships at top children's hospitals. The single-use band consumable design supports a recurring revenue model on top of initial device placements. Pricing is not publicly disclosed; customers contact the company directly. The company is also pursuing adjacent customer segments including postpartum maternal health (via the March of Dimes Innovation Fund investment and NIH RADx Tech for Maternal Health Challenge) and adult hypertension home monitoring.
The company is venture-backed, having closed a $6 million Series A financing in April 2021 led by GSR Ventures with co-investments from Keytone Ventures and XTX Ventures, and has received follow-on capital from March of Dimes Innovation Fund, Additional Ventures ($50K in October 2024), and multiple non-dilutive grants (CTIP CPI Grant, AAP SOATT/SWPDC Pediatric Device Award, Bear Institute PACK Challenge, SBIR Phase I grants from NIH NICHD and USAF AFWERX). The board and leadership combine deep technical and commercial expertise: CEO and co-founder Xina Quan, PhD (MIT/Princeton, 30+ patents, ex-AT&T Bell Labs, Cambrios, DigiLens); co-founder Zhenan Bao, PhD (Stanford, National Academy of Engineering, 60+ patents, founder of Stanford Wearable Electronics Initiative); Executive Chairman Peter Noymer, PhD (ex-CEO Kedalion, ex-COO SteadyMed); and COO Will Sutherland (35+ years in product introductions).
PyrAmes, Inc. firmographics
Firmographics- Name
- PyrAmes, Inc.
- Legal name
- PyrAmes, Inc.
- Website
- https://pyrameshealth.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PyrAmes, Inc. is a Cupertino-based digital health company developing FDA-cleared Boppli® and pipeline Bosimi® continuous non-invasive blood pressure monitors, using proprietary capacitive sensors and machine-learning algorithms to serve NICU, adult inpatient, and home hypertension markets.
- Ownership category
- akta.pro rank
PyrAmes, Inc. industry classification
Industry- Product category
- Continuous Non-Invasive Blood Pressure Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Pressure Monitoring (Cuff & Cuffless) (HLAHACAC)
- akta.pro secondary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where PyrAmes, Inc. is headquartered
LocationHeadquarters
- HQ city
- Cupertino
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PyrAmes, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales (Hardware): PyrAmes generates revenue through the sale of its medical device platforms (Boppli®, Bosimi®, Bosimi@Home™) and associated sensors/band accessories to hospitals, healthcare systems, and care providers. Boppli is described as a single-use device, suggesting a consumables/repeat-purchase revenue model in addition to device unit sales. Boppli received FDA 510(k) clearance and is commercially available. Bosimi and Bosimi@Home are under development and not yet cleared for distribution.
- Series A Financing: PyrAmes raised $6 million in Series A financing led by GSR Ventures with co-investments from Keytone Ventures and XTX Ventures, intended to accelerate commercialization, pilot-scale manufacturing, clinical validation studies, and regulatory reviews.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Boppli® - Neonatal/Pediatric cNIBP (FDA cleared, commercially available) |
| Unit Pricing | Pay-as-you-go | Bosimi® - Adult Inpatient cNIBP (under development, not FDA cleared) |
| Unit Pricing | Pay-as-you-go | Bosimi@Home™ - Adult Outpatient/Home Monitoring (under development, not FDA cleared) |
Go-to-market motion3 records
Distribution channels1 record
Marketing channels6 records
PyrAmes, Inc. product offering
Product offeringCore offering
PyrAmes develops and sells wearable medical devices that enable continuous, non-invasive blood pressure (cNIBP) monitoring. Its lead product, Boppli®, is an FDA 510(k)-cleared single-use wearable band used in NICUs to monitor blood pressure in infants without invasive arterial lines. The company also has two additional platforms under development — Bosimi® for adult inpatient/emergency care and Bosimi@Home™ for outpatient and home use — all based on proprietary capacitive sensors combined with machine learning algorithms.
Product overview
PyrAmes is a digital health company that has developed a proprietary sensor platform providing continuous blood pressure monitoring that is accurate, wireless, and non-invasive. The company's product portfolio consists of three distinct platforms: Boppli® for neonatal and pediatric patients in the NICU (FDA 510(k) cleared), Bosimi® for adult inpatient and emergency care (under development), and Bosimi@Home™ for outpatient diagnostics and home medical management (under development). All platforms share common underlying technology including capacitive sensors and machine learning algorithms that extract blood pressure values from pulse waveform data, with components including wearable bands and paired devices (bedside device or mobile application).
Differentiator
Problem solved
Functional benefit
Brands
- Boppli®: Continuous non-invasive blood pressure monitoring platform for neonatal and pediatric patients in the NICU
- Bosimi®
- Bosimi@Home™
Products and services
- Boppli® A continuous, non-invasive blood pressure (cNIBP) monitoring system for neonatal and pediatric patients in the NICU. Uses a single-use, battery-powered wearable band with capacitive sensors placed on the infant's arm or foot, streaming data wirelessly to a bedside device that displays real-time mean arterial pressure, systolic BP, diastolic BP, and pulse rate with up to 72-hour wear time and no external calibration required.
- Bosimi® An adult inpatient and emergency care continuous non-invasive blood pressure monitoring platform consisting of a wearable band sensor and bedside device. Uses machine-learning algorithms to provide real-time BP monitoring where invasive arterial lines are contraindicated or impractical, detecting rapid changes in blood pressure for timely clinical decisions.
- Bosimi@Home™ Monitoring An outpatient monitoring platform for diagnostics, treatment validation, and home medical management. Consists of a lightweight, low-power, moisture-resistant wireless wearable band paired with a mobile application that provides continuous BP measurements, live monitoring, and historical data storage for adults managing hypertension, postpartum maternal health, and chronic conditions.
Quantifiable outcome
- Boppli accuracy was demonstrated to be within FDA guidelines during a rigorous pivotal clinical study comparing Boppli sensor data against simultaneous arterial line data for critically ill infants in multiple NICUs in the U.S. and Canada.
- +2 more outcomes
Companies that use PyrAmes, Inc.
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
PyrAmes, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
PyrAmes, Inc. partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, major and minor.
- Children's National Hospital (NICU)coreChildren's National Hospital served as a clinical site in PyrAmes' pivotal study for Boppli and was among the first NICUs to adopt the Boppli technology commercially. Dr. Lamia Soghier, Medical Director and Quality & Safety Officer of the NICU, provided a testimonial praising Boppli's ability to non-invasively monitor BP in fragile babies without the complications of arterial lines. Children's National is a premier pediatric hospital affiliated with the NCC-PDI pediatric device consortium.
- March of DimesmajorMarch of Dimes invested in PyrAmes through its Innovation Fund (the third investment for the fund, a venture philanthropy initiative) to support development and commercialization of wearable technology to non-invasively monitor blood pressure for new mothers and babies. March of Dimes selected PyrAmes for its potential to improve outcomes for moms and babies through more effective blood pressure monitoring. March of Dimes is the leading organization fighting for the health of moms and babies with an 85-year legacy.
- NIH RADx Tech for Maternal Health ChallengemajorPyrAmes was one of only 10 companies selected for the final Technology Assessment phase of the NIH RADx Tech for Maternal Health Challenge. The goal of the RADx Challenge is to improve maternal health outcomes through innovative home-based or point-of-care diagnostic devices, wearables, and remote sensing technologies. PyrAmes' submission focused on the Bosimi platform for postpartum maternal health monitoring, working with the NIH team to accelerate development, overcome technological, clinical, usability, regulatory, and commercialization hurdles.
- SenteccoreSentec and PyrAmes established an exclusive commercial distribution partnership to bring Boppli, PyrAmes' first continuous non-invasive blood pressure device, to neonatal intensive care teams throughout the United States. Sentec, a market leader in non-invasive NICU monitoring (transcutaneous CO2), leverages its established customer relationships at top NICUs globally. Bob Cormier, President of Sentec North America, stated that Sentec is 'humbled and enthusiastic' to offer Boppli as another option for non-invasive monitoring advancing neuroprotective care goals.
- Zhenan Bao (Stanford University)coreProfessor Zhenan Bao, K.K. Lee Professor in Chemical Engineering at Stanford University, is a co-founder of PyrAmes, serves on the Board of Directors, and acts as an Advisor. She is a world-renowned researcher in electronics and wearables, a member of the National Academy of Engineering and National Academy of Inventors. She founded and directs the Stanford Wearable Electronics Initiative. Zhenan and Xina Quan previously worked together at AT&T Bell Labs. She has over 400 refereed publications and over 60 US patents. Her lab's expertise in flexible electronics and sensors has been foundational to PyrAmes' technology development.
- UCSF-Stanford Pediatric Device ConsortiumminorPyrAmes is a member of the UCSF-Stanford Pediatric Device Consortium, a federally-funded program to support development of pediatric medical devices. The consortium provides mentorship, resources, and connections to help innovators bring pediatric devices to market.
- LG NOVAminorPyrAmes was selected by LG Electronics North American Innovation Center (LG NOVA) in its inaugural 'First 50' cohort from over 1,300 applicants in the Mission for the Future global challenge competition. Companies work with LG NOVA's incubation team on joint business proposals, access to LG's global network, expertise, mentorship, and capital. Focus area: Connected Health.
- Plug and Play JapanminorSelected for Plug and Play Japan's Winter/Spring 2022 Batch Accelerator Program (49 corporate partners, 67 companies from Japan, U.S., Canada, India, UK, Spain). PyrAmes participated in the Health track, focusing on sensors and wearables, receiving business development resources and access to Plug and Play's global network.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
PyrAmes, Inc. competitors and assessment
Company assessmentDirect peers
- Caretaker Medical: Caretaker Medical markets a wireless, continuous non-invasive blood pressure (cNIBP) monitor using a finger-cuff/arterial-pressure-derived approach. Like PyrAmes, it targets the unmet need for beat-to-beat BP without arterial lines, making it the closest functional direct peer, although it is focused on adult care rather than neonates.
- Biobeat: Biobeat develops cuffless, continuous BP and vital-sign monitoring wearables using PPG-based sensors. Its single-use/chest-worn patches overlap with PyrAmes' Bosimi@Home and Bosimi platforms in providing non-invasive continuous BP, making it a direct competitor in adult ambulatory/inpatient use cases.
- Aktiia: Aktiia offers CE-marked cuffless continuous BP monitoring using a wrist-worn optical sensor paired with an arm cuff for periodic calibration. It is a direct competitor to PyrAmes' Bosimi@Home platform in the home/outpatient hypertension market.
Broad incumbents
- Masimo: Masimo is a leading patient-monitoring company with rainbow SET pulse CO-oximetry and rainbow acoustic monitoring deployed in NICUs and adult ICUs globally. Its established hospital relationships and multi-parameter bedside monitors represent the broader competitive context into which PyrAmes' Boppli and Bosimi devices must be sold.
- Edwards Lifesciences: Edwards Lifesciences dominates invasive hemodynamic monitoring (FloTrac, ClearSight, non-invasive finger cuff systems such as Acumen IQ) used in ORs and ICUs. Its non-invasive ClearSight product competes conceptually with PyrAmes' Bosimi, while its flagship invasive monitoring defines the existing standard PyrAmes aims to displace.
- GE HealthCare: GE HealthCare provides multi-parameter patient monitors (CARESCAPE, Giraffe for NICUs) widely used in hospital ICUs and NICUs. As a broad incumbent, it shapes hospital purchasing cycles and represents the dominant platform against which add-on cNIBP technologies like Boppli must integrate.
- Philips (Patient Monitoring): Philips offers patient monitoring systems (IntelliVue) and connected biosensor solutions used across NICUs and adult wards. Its installed base and analytics ecosystem position it as a broad incumbent competitor in continuous BP and vital-sign monitoring markets targeted by PyrAmes.
- Omron Healthcare: Omron is the global leader in home and clinical blood-pressure cuffs and is moving into connected and wearable BP devices. Its dominance in BP monitoring (home, clinical, and emerging cuffless) makes it the leading incumbent against which PyrAmes' Bosimi@Home and Boppli compete.
Emerging players
- Withings: Withings produces connected blood pressure monitors (BPM Connect, Core) and broader consumer health devices. While not a continuous cuffless competitor, it competes in the consumer/home BP monitoring category that Bosimi@Home is targeting.
Others
- Sentec: Sentec is PyrAmes' exclusive U.S. distribution partner for Boppli and a market leader in non-invasive NICU monitoring (transcutaneous CO2). Although it is a partner rather than a competitor, its portfolio of NICU sensors positions it as a directly adjacent peer whose customer relationships PyrAmes leverages to enter NICUs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PyrAmes, Inc. social profiles
Digital presencePyrAmes, Inc. compliance and trust
Trust signalCompliance2 records
PyrAmes, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
PyrAmes, Inc. leadership team
Management profileNumber of profiles
Profiles8 records
PyrAmes, Inc. funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PyrAmes, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PyrAmes, Inc.
What does PyrAmes, Inc. do?
PyrAmes develops and sells wearable medical devices that enable continuous, non-invasive blood pressure (cNIBP) monitoring. Its lead product, Boppli®, is an FDA 510(k)-cleared single-use wearable band used in NICUs to monitor blood pressure in infants without invasive arterial lines. The company also has two additional platforms under development — Bosimi® for adult inpatient/emergency care and Bosimi@Home™ for outpatient and home use — all based on proprietary capacitive sensors combined with machine learning algorithms.
Is PyrAmes, Inc. a public or private company?
PyrAmes, Inc. is a private company. It is classified as venture growth investor backed and is currently operating.
When was PyrAmes, Inc. founded?
PyrAmes, Inc. was founded in 2015. It employs 1 to 10 people.
Where is PyrAmes, Inc. based?
PyrAmes, Inc. is headquartered in Cupertino, United States, in the North America region.
How does PyrAmes, Inc. make money?
Two revenue lines are on record. Medical Device Sales (Hardware) is the primary driver. The others are series A Financing.
Who are PyrAmes, Inc.'s main competitors?
Direct peers on record are Caretaker Medical, Biobeat and Aktiia. Broad incumbents are Masimo, Edwards Lifesciences, GE HealthCare, Philips (Patient Monitoring) and Omron Healthcare. Withings is listed as an emerging player. Sentec is listed as an others.
Does PyrAmes, Inc. have an API?
No public API is recorded for PyrAmes, Inc..
What industry is PyrAmes, Inc. in?
PyrAmes, Inc.'s product category is Continuous Non-Invasive Blood Pressure Monitoring Devices. Its primary akta.pro industry code is HLAHACAC, Blood Pressure Monitoring (Cuff & Cuffless), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 334510 and its SIC code is 3845.